Rhythm Pharmaceuticals (MEX:RYTM) Other Current Receivables: MXN0 Mil (As of Mar. 2026)


MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
55 GF Score
Price MXN1,866.76
GF Value MXN1,817.22
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Other Current Receivables?

Rhythm Pharmaceuticals MEX:RYTM 55 Other Current Receivables is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:RYTM with a GF Score™ of 55/100 and a GF Value™ of MXN1,817.22. The stock has 3 warning signs investors should review.

Rhythm Pharmaceuticals's Other Current Receivables for the quarter that ended in Mar. 2026 was MXN0 Mil.

Rhythm Pharmaceuticals Other Current Receivables Related Terms

Rhythm Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Other Current Receivables Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rhythm Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:RYTM
55GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of MXN0 Mil mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Other Current Receivables of MXN0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Other Current Receivables too high?
Rhythm Pharmaceuticals' current Other Current Receivables is MXN0 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Other Current Receivables compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Other Current Receivables of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Other Current Receivables is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Other Current Receivables of MXN0 Mil. The stock's GF Value™ is MXN1,817.22, compared to a current price of MXN1,866.76 — trading 2.7% above its estimated fair value. The current Other Current Receivables is MXN0 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Other Current Receivables is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,866.76 is trading 2.7% above its estimated GF Value™ of MXN1,817.22.

Key valuation signals for MEX:RYTM:

  • Other Current Receivables: MXN0 Mil
  • GF Value™: MXN1,817.22 vs. price of MXN1,866.76 (2.7% above fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
55GF Score

Get the complete analysis for MEX:RYTM

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,817.22
GF Value